ASPIC

Hotel Crowne Plaza, Athens, Greece

12- 13 June, 2015

See more informations here: http://www.eacr.org/user_uploads/files/meetings/SAVE%20THE%20DATE%20IMMUNOLOGY%208.pdf

Atmosfera m, Rua Júlio Dinis, nº 158/160, 5^th floor, Porto, Portugal 

02 July, 2015

See more informations here: http://www.sicr2015.ineb.up.pt/
 

Recently, the Portuguese press announced in several front pages that a private Foundation (Fundação Champalimaud) was capable to cure 90% of cancer patients with single dose radiotherapy. This announcement was very unfortunate. It is obviously a false statement from the professionals and scientists standpoint, but not for patients. Patients and their families tend to invest their expectations in whatever promise, even if the “good news” may sound as suspicious to everybody that is not sufficiently acquainted with science progress (and limitations).

Recently, the Portuguese press announced in several front pages that a private Foundation (Fundação Champalimaud) was capable to cure 90% of cancer patients with single dose radiotherapy. This announcement was very unfortunate. It is obviously a false statement from the professionals and scientists standpoint, but not for patients. Patients and their families tend to invest their expectations in whatever promise, even if the “good news” may sound as suspicious to everybody that is not sufficiently acquainted with science progress (and limitations).

Budapest, Hungary

19-21 November, 2015

See more informations here: http://www.oncology.hu/mot2015/?page=kedves_kollegak_vendegeink_barataim_

Budapest, Hungary

19-21 November, 2015

See more informations here: http://www.oncology.hu/mot2015/?page=kedves_kollegak_vendegeink_barataim_

Authors and Affiliations:

Diana Campos^1,2, Daniela Freitas², Joana Gomes², Ana Magalhães², Catharina Steentoft¹, Catarina Gomes², Malene B. Vester-Christensen^1*, José Alexandre Ferreira^3,4, Luis P. Afonso⁵, Lúcio L. Santos³, João Pinto de Sousa⁶, Ulla Mandel¹, Henrik Clausen¹, Sergey Y. Vakhrushev¹, Celso A. Reis^2,6,7

Este trabalho realizado em colaboração por várias instituições de investigação (IPATIMUP, IPO-Porto, Faculdade de Medicina e ICBAS da Universidade do Porto, Universidade de Aveiro, e Universidade de Copenhaga), e publicado na Molecular & Cellular Proteomics, caracterizou o O-glicoproteoma de células gástricas geneticamente modificadas com o objetivo de identificar potenciais biomarcadores específicos do carcinoma gástrico. O estudo permitiu ainda a identificação de glicoformas aberrantes expressas em proteínas em circulação no soro de doentes com carcinomas gástricos.

Researcher Noel Miranda, who has focused his work in the treatment of colorectal cancer, was honored by the American Association for Cancer Research (AACR) with a grant of 93 thousand euros. Currently doing research at the Medical Center of the Leiden University (Netherlands), this 32 year old researcher now has the opportunity to pursue studies in this area and establish his own research group in the future.